Hadasit Bio-Holdings Ltd
HBL - Hadasit Bio-Holdings Ltd operates in the biotechnology industry in Israel. It operates in the fields of oncology, regenerative medicine, and inflammatory disease. The company develops biological drugs; and plasma RNA biomarkers for colorectal cancer. It offers ProtAb, an immunotherapeutic monoclonal antibody for the treatment of autoimmune inflammatory diseases. HBL - Hadasit Bio-Holdings L… Read more
Hadasit Bio-Holdings Ltd - Asset Resilience Ratio
Hadasit Bio-Holdings Ltd (HSITF) has an Asset Resilience Ratio of 38.14% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2012–2023)
This chart shows how Hadasit Bio-Holdings Ltd's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Hadasit Bio-Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $2.13 Million | 38.14% |
| Total Liquid Assets | $2.13 Million | 38.14% |
Asset Resilience Insights
- Very High Liquidity: Hadasit Bio-Holdings Ltd maintains exceptional liquid asset reserves at 38.14% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Hadasit Bio-Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Hadasit Bio-Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
ESSA Pharma Inc
NASDAQ:EPIX |
Biotechnology | 21.42% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
Annual Asset Resilience Ratio for Hadasit Bio-Holdings Ltd (2012–2023)
The table below shows the annual Asset Resilience Ratio data for Hadasit Bio-Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 94.00% | $7.58 Million | $8.06 Million | +55.35pp |
| 2022-12-31 | 38.65% | $15.06 Million | $38.95 Million | +6.56pp |
| 2021-12-31 | 32.09% | $21.32 Million | $66.41 Million | -47.03pp |
| 2020-12-31 | 79.12% | $32.74 Million | $41.38 Million | +65.75pp |
| 2019-12-31 | 13.37% | $1.26 Million | $9.41 Million | +8.70pp |
| 2018-12-31 | 4.67% | $1.65 Million | $35.34 Million | -47.15pp |
| 2017-12-31 | 51.82% | $35.55 Million | $68.60 Million | +0.51pp |
| 2016-12-31 | 51.31% | $35.64 Million | $69.46 Million | +49.76pp |
| 2015-12-31 | 1.54% | $1.06 Million | $68.61 Million | -13.40pp |
| 2014-12-31 | 14.95% | $4.84 Million | $32.42 Million | -8.97pp |
| 2013-12-31 | 23.92% | $8.31 Million | $34.76 Million | -3.34pp |
| 2012-12-31 | 27.25% | $11.77 Million | $43.19 Million | -- |